Zoledronic acid combined with androgen-deprivation therapy may prolong time to castration-resistant prostate cancer in hormone-naïve metastatic prostate cancer patients-A propensity scoring approach

doi:10.1016/j.ajur.2015.10.003

Asian Journal of Urology, 2016, 3 (1): 33-38 doi: 10.1016/j.ajur.2015.10.003

Original Article

Zoledronic acid combined with androgen-deprivation therapy may prolong time to castration-resistant prostate cancer in hormone-naïve metastatic prostate cancer patients-A propensity scoring approach

Kazuhiro Nagao^a, Hideyasu Matsuyama^a, Masahiro Nozawa^b, Isao Hara^c, Tsukasa Nishioka^d, Takahiro Komura^e, Atsunobu Esa^f, Shigeya Uejima^g,h, Masaaki Imanishiⁱ, Yasunari Uekado^j, Takatoshi Ogawa^k, Hiroshi Kajikawa^l, Hirotsugu Uemura^b

a Department of Urology, Graduate School of Medicine, Yamaguchi University, Japan;
b Department of Urology, Kinki University Faculty of Medicine, Japan;
c Department of Urology, Wakayama Medical University School of Medicine, Japan;
d Department of Urology, Sakai Hospital, Kinki University Faculty of Medicine, Japan;
e Department of Urology, Naga Hospital, Japan;
f Department of Urology, NTT Osaka Hospital, Japan;
g Department of Urology, National Hospital Organization Osaka Minami Medical Center, Japan;
h Department of Urology, Nara Hospital Kinki University Faculty of Medicine, Japan;
i Department of Urology, Tondabayashi Hospital, Japan;
j Department of Urology, Wakayama Rosai Hospital, Japan;
k Department of Urology, Kainan Municipal Hospital, Japan;
l Department of Urology, Izumiotsu Municipal Hospital, Japan

Abstract
Related Citation (1)

Download:

HTML

PDF (2260KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To clarify the oncological benefit of zoledronic acid for hormone-naïve metastatic prostate cancer, patient outcome of androgen deprivation therapy with zoledronic acid (ADT + Z) and androgen deprivation therapy alone (ADT) was compared.
Methods: Fifty-two patients with pathologically confirmed metastatic prostate cancer were prospectively enrolled and treated with combined androgen blockade (goserelin and bicalutamide) with zoledronic acid (4 mg every 4 weeks for 24 months). A propensity score-match with logistic regression analysis was applied to select 50 pair-matched cohorts (both from ADT + Z and from historical control cohorts who had undergone ADT alone), and patient outcomes were compared.
Results: Patients with ADT + Z had significantly longer time to progression (TTP) than those with ADT (median TTP; 24.2 vs. 14.0 months, p = 0.0092), while no significant difference of overall survival between two groups (p = 0.1502). Multivariate analysis for biochemical recurrence revealed treatment with ADT was the sole independent prognostic factor (HR: 1.724, 95% CI: 1.06-2.86, p = 0.0297).
Conclusion: Combination of zoledronic acid with ADT may prolong time to castration resistant prostate cancer.

Key words： Zoledronic acid Hormone-naï ve prostate cancer Biochemical recurrence Propensity scorematch analysis

Received: 07 April 2015 Published: 29 January 2016

Corresponding Authors: Hideyasu Matsuyama E-mail: hidde@yamaguchi-u.ac.jp

	Service
	E-mail this article
	Add to citation manager
	E-mail Alert
	Articles by authors
	Kazuhiro Nagao
	Hideyasu Matsuyama
	Masahiro Nozawa
	Isao Hara
	Tsukasa Nishioka
	Takahiro Komura
	Atsunobu Esa
	Shigeya Uejima
	Masaaki Imanishi
	Yasunari Uekado
	Takatoshi Ogawa
	Hiroshi Kajikawa
	Hirotsugu Uemura

TRENDMD:

Cite this article:

Kazuhiro Nagao,Hideyasu Matsuyama,Masahiro Nozawa, et al. Zoledronic acid combined with androgen-deprivation therapy may prolong time to castration-resistant prostate cancer in hormone-naïve metastatic prostate cancer patients-A propensity scoring approach[J]. Asian Journal of Urology, 2016, 3(1): 33-38.

URL:

http://www.ajurology.com/EN/10.1016/j.ajur.2015.10.003 OR http://www.ajurology.com/EN/Y2016/V3/I1/33

[1]	Saad F, Adachi JD, Brown JP, Canning LA, Gelmon KA, Josse RG, et al. Cancer treatment-induced bone loss in breast and prostate cancer. J Clin Oncol 2008;26:5465-76.
[2]	Russell RG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008;19:733-59.
[3]	National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Prostate cancer version 1. 2013. http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf.
[4]	Winter MC, Holen I, Coleman RE. Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev 2008;34:453-75.
[5]	Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94: 1458-68.
[6]	Kamiya N, Suzuki H, Endo T, Takano M, Yano M, Naoi M, et al. Additive effect of zoledronic acid on serum prostate-specific antigen changes for hormone-sensitive prostate cancer patients with bone metastasis treated by combined androgen blockade. Int J Urol 2012;19:169-73.
[7]	Okegawa T, Higaki M, Matsumoto T, Kase H, Murata A, Noda K, et al. Zoledronic acid improves clinical outcomes in patients with bone metastatic hormone-naïve prostate cancer in a multicenter clinical trial. Anticancer Res 2014;34:4415-20.
[8]	Uemura H, Yanagisawa M, Ikeda I, Fujinami K, Iwasaki A, Noguchi S, et al. Bone Metastasis Study Group. Possible antitumor activity of initial treatment with zoledronic acid with hormonal therapy for bone-metastatic prostate cancer in multicenter clinical trial. Int J Clin Oncol 2013;18:472-7.
[9]	Ueno S, Mizokami A, Fukagai T, Fujimoto N, Oh-Oka H, Kondo Y, et al. Efficacy of combined androgen blockade with zoledronic acid treatment in prostate cancer with bone metastasis: the ZABTON-PC (zoledronic acid/androgen blockade trial on prostate cancer) study. Anticancer Res 2013;33:3837-44.
[10]	Nozawa M, Inagaki T, Nagao K, Nishioka T, Komura T, Esa A, et al. Phase II trial of zoledronic acid combined with androgen-deprivation therapy for treatment-naïve prostate cancer with bone metastasis. Int J Clin Oncol 2014;19: 693-701.
[11]	Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997;127:757.
[12]	Connors Jr AF, Speroff T, Dawson NV, Thomas C, Harrell Jr FE, Wagner D, et al. The effectiveness of right heart catheterization in the initial care of critically ill patients. SUPPORT Investigators. JAMA 1996;276:889-97.
[13]	D'Agostino Jr RB. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998;17:2265.
[14]	Tewari A, Divine D, Chang P, Shemtov MM, Milowsky M, Nanus D, et al. Long-term survival in men with high grade prostate cancer: a comparison between conservative treatment, radiation therapy and radical prostatectomyea propensity scoring approach. J Urol 2007;177:911-5.
[15]	Shimabukuro T, Sakano S, Matsuda K, Kamiryo Y, Yamamoto N, Kaneda Y, et al. Can docetaxel therapy improve overall survival from primary therapy compared with androgendeprivation therapy alone in Japanese patients with castration-resistant prostate cancer? A multi-institutional cooperative study. Int J Clin Oncol 2013;18:62-7.
[16]	SantiniD,Vincenzi B,Galluzzo S, Battistoni F, Rocci L,Venditti O, et al. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Cancer Res 2007;13(15 Pt 1):4482-6.
[17]	Williamson EJ, Forbes A, White IR. Variance reduction in randomized trials by inverse probability weighting using the propensity score. Stat Med 2014;33:721-37.
[18]	Xu Z, Kalbfleisch JD. Propensity score matching in randomized clinical trials. Biometrics 2010;66:813-23.